Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED)

v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY (UNAUDITED) - USD ($)
Total
Common Stock Warrants
Prefunded Warrants
Common Stock
Common Stock
Common Stock Warrants
Common Stock
Prefunded Warrants
Additional Paid-In Capital
Additional Paid-In Capital
Common Stock Warrants
Additional Paid-In Capital
Prefunded Warrants
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021       1,904,434            
Beginning balance at Dec. 31, 2021 $ 5,864,166     $ 1,904     $ 53,118,425     $ (47,256,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       600            
Stock-based compensation expense 150,358     $ 1     150,357      
Exercise warrant (in shares)           78,667        
Exercise warrant     $ 1,967     $ 79     $ 1,888  
Net loss (3,043,399)                 (3,043,399)
Ending balance (in shares) at Mar. 31, 2022       1,983,701            
Ending balance at Mar. 31, 2022 2,973,092     $ 1,984     53,270,670     (50,299,562)
Beginning balance (in shares) at Dec. 31, 2021       1,904,434            
Beginning balance at Dec. 31, 2021 5,864,166     $ 1,904     53,118,425     (47,256,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (9,589,960)                  
Ending balance (in shares) at Sep. 30, 2022       1,983,701            
Ending balance at Sep. 30, 2022 (3,284,981)     $ 1,984     53,559,158     (56,846,123)
Beginning balance (in shares) at Mar. 31, 2022       1,983,701            
Beginning balance at Mar. 31, 2022 2,973,092     $ 1,984     53,270,670     (50,299,562)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense 144,364           144,364      
Net loss (3,419,278)                 (3,419,278)
Ending balance (in shares) at Jun. 30, 2022       1,983,701            
Ending balance at Jun. 30, 2022 (301,822)     $ 1,984     53,415,034     (53,718,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       0            
Stock-based compensation expense 144,124     $ 0     144,124      
Net loss (3,127,283)                 (3,127,283)
Ending balance (in shares) at Sep. 30, 2022       1,983,701            
Ending balance at Sep. 30, 2022 (3,284,981)     $ 1,984     53,559,158     (56,846,123)
Beginning balance (in shares) at Dec. 31, 2022       3,654,119            
Beginning balance at Dec. 31, 2022 (3,008,054)     $ 3,654     63,726,057     (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       0            
Stock-based compensation expense 131,579     $ 0     131,579      
Exercise warrant (in shares)         66,566          
Exercise warrant   $ 282,905     $ 66     $ 282,839    
Stock issued during period, shares, conversion of convertible securities       165,517            
Conversion of multi-draw credit agreement - related party and accrued interest 2,980,521     $ 166     2,980,355      
Net loss (5,167,520)                 (5,167,520)
Ending balance (in shares) at Mar. 31, 2023       3,886,202            
Ending balance at Mar. 31, 2023 (4,780,569)     $ 3,886     67,120,830     (71,905,285)
Beginning balance (in shares) at Dec. 31, 2022       3,654,119            
Beginning balance at Dec. 31, 2022 (3,008,054)     $ 3,654     63,726,057     (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (33,224,854)                  
Ending balance (in shares) at Sep. 30, 2023       12,338,910            
Ending balance at Sep. 30, 2023 1,695,258     $ 12,338     101,645,539     (99,962,619)
Beginning balance (in shares) at Mar. 31, 2023       3,886,202            
Beginning balance at Mar. 31, 2023 (4,780,569)     $ 3,886     67,120,830     (71,905,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense 102,871           102,871      
Net loss (3,111,500)                 (3,111,500)
Ending balance (in shares) at Jun. 30, 2023       3,886,202            
Ending balance at Jun. 30, 2023 (7,789,198)     $ 3,886     67,223,701     (75,016,785)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense 160,207           160,207      
Number of shares issued (in shares)       2,989,981            
PIPE financing, net of equity issuance costs of 265,053 11,734,947     $ 2,990     11,731,957      
Common stock issued in acquisition of IPR&D asset (in shares)       5,436,378            
Common stock issued in acquisition of IPR&D asset 21,609,586     $ 5,436     21,604,150      
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 925,550           925,550      
Stock Issued During Period, Shares, Reverse Stock Splits       26,349            
Common stock issued for fractional share adjustment in reverse stock split 0     $ 26     (26)      
Net loss (24,945,834)                 (24,945,834)
Ending balance (in shares) at Sep. 30, 2023       12,338,910            
Ending balance at Sep. 30, 2023 $ 1,695,258     $ 12,338     $ 101,645,539     $ (99,962,619)